Letermovir
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cytomegalovirus Disease
Conditions
Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
Trial Timeline
Jan 5, 2022 → Jan 14, 2025
NCT ID
NCT04904614About Letermovir
Letermovir is a approved stage product being developed by Merck for Cytomegalovirus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04904614. Target conditions include Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07199465 | Phase 1 | Recruiting |
| NCT06407232 | Phase 3 | Recruiting |
| NCT05789615 | Pre-clinical | Completed |
| NCT05763823 | Phase 3 | Completed |
| NCT04904614 | Approved | Completed |
| NCT04312841 | Phase 2 | Completed |
| NCT03728426 | Phase 2 | Completed |
Competing Products
20 competing products in Cytomegalovirus Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP0113 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Letermovir oral granules + Letermovir tablet + Letermovir intravenous | Merck | Phase 2 | 52 |
| Letermovir 240 mg Oral Tablet | Merck | Phase 2 | 52 |
| Letermovir tablet + Letermovir IV | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 1 | 33 |
| Letermovir 480 MG [Prevymis] | Merck | Phase 2 | 52 |
| V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID | Merck | Phase 1 | 33 |
| Ganciclovir | Merck | Pre-clinical | 23 |
| Letermovir + Placebo | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 2 | 52 |
| V160 + Placebo | Merck | Phase 2 | 52 |
| V160 | Merck | Phase 1 | 33 |
| Letermovir | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 3 | 77 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Zidovudine + Didanosine + Ganciclovir | Roche | Phase 1 | 33 |
| Valganciclovir | Roche | Pre-clinical | 23 |
| Foscarnet sodium + Ganciclovir | Roche | Phase 1 | 33 |
| Valganciclovir + Valganciclovir | Roche | Phase 3 | 77 |